Follow The Filings

GALT Galectin Therapeutics Inc.

Health Care, filed as GALECTIN THERAPEUTICS INC (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • $218K
  • 1 reduce

In 2026 Q2 Murray Stahl trimmed Galectin Therapeutics.

Who owns GALT

Sorted by value, long equity only, as of 2026 Q2.

History
Murray Stahl, Horizon Kinetics Asset Management <0.01% Reduce −4.6% 46,968 $218K History

1 current, options excluded

Insider trades

Open-market buys and sales by GALT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All GALT insider trades
  • $26K bought by 2 insiders
  • $1.3M sold by 1 insider outside a trading plan
  • $4.6M sold by 4 insiders under 10b5-1 plans
  1. Khurram Jamil Chief Medical Officer
    Planned sale
    $83K 16,250 shares at $5.13 100% of stake
    Traded Jul 14 Filed Jul 16
    ↗
  2. Harold H. Shlevin Director
    Planned sale
    $151K 30,000 shares at $5.03 82% of stake
    Traded Jun 26–29 Filed Jun 30
    ↗
  3. Khurram Jamil Chief Medical Officer
    Planned sale
    $262K 52,037 shares at $5.04 100% of stake
    Traded Jun 26–29 Filed Jun 30
    ↗
  4. Khurram Jamil Chief Medical Officer
    Planned sale
    $24K 7,557 shares at $3.14 100% of stake
    Traded Jun 23 Filed Jun 25
    ↗
  5. Khurram Jamil Chief Medical Officer
    Planned sale
    $1,761 568 shares at $3.10 100% of stake
    Traded May 26 Filed May 28
    ↗
  6. Kary Eldred Director
    Buy
    $810 300 shares at $2.70 +0.5% to stake
    Traded Feb 6 Filed Feb 9
    ↗
  7. Joel Lewis CEO
    Planned sale
    $321K 84,000 shares at $3.82 9.2% of stake
    Traded Jan 2–6 Filed Jan 6
    ↗
  8. Jack W Callicutt CFO
    Planned sale
    $233K 60,000 shares at $3.89 89% of stake
    Traded Jan 2–6 Filed Jan 6
    ↗
  9. Khurram Jamil Chief Medical Officer
    Planned sale
    $232K 60,000 shares at $3.87
    Traded Jan 2–6 Filed Jan 6
    ↗
  10. Khurram Jamil Chief Medical Officer
    Planned sale
    $33K 8,125 shares at $4.07 100% of stake
    Traded Dec 31, 2025 Filed Jan 5
    ↗
  11. Kevin D Freeman Director
    Buy
    $20K 5,500 shares at $3.55 +11% to stake
    Traded Dec 23, 2025 Filed Dec 23, 2025
    ↗
  12. Kary Eldred Director
    Buy
    $2,611 700 shares at $3.73 +1.1% to stake
    Traded Dec 23, 2025 Filed Dec 23, 2025
    ↗
  13. Joel Lewis CEO
    Planned sale
    $55K 7,829 shares at $7.06 0.9% of stake
    Traded Dec 17, 2025 Filed Dec 19, 2025
    ↗
  14. Khurram Jamil Chief Medical Officer
    Planned sale
    $137K 19,442 shares at $7.04 100% of stake
    Traded Dec 17, 2025 Filed Dec 19, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 53 option exercises, 2 other transactions, and 1 stock grant.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
DEF 14A Filing Doc
DEFA14A Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 3.02,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 5.02 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$41.07M -$47.05M -$30.84M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $27.71M $17.25M $19.44M
Total non-current assets * $490,000 $243,000 $96,000
Total assets $28.2M $17.5M $19.53M
Total current liabilities $15.68M $35.41M $8.03M
Total non-current liabilities * $72.76M $85.16M $137.7M
Total equity -$61.96M -$104.79M -$127.92M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$32.96M -$41.77M -$23.88M
Cash from investing $0.00 $0.00 $0.00
Cash from financing $40.03M $31.23M $26.48M
Net change in cash * $7.07M -$10.54M $2.6M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.